Screening and diagnosis

Classification and risk stratification

Perioperative care

Quality improvement

Patient education

Nonpharmacologic interventions

Therapeutic procedures

Respiratory support

Follow-up and surveillance

Specific circumstances

Preventative measures

Medical management

Surgical interventions

Inpatient care

Diagnostic procedures

Diagnostic investigations

Insufficient evidence to make a recommendation.

Strongly favor this test or intervention.

The Cairo-Bishop criteria calculator is a tool used to assess the presence of clinical tumor lysis syndrome (TLS) by analyzing specific laboratory and clinical parameters. It helps determine if the diagnostic criteria for TLS are met by evaluating combinations of biochemical changes and clinical manifestations typically associated with the condition.

The laboratory criteria involve several key metabolic markers:
- Uric acid: ≥ 476 mcmol/L or a 25% increase from baseline
- Potassium: ≥ 6.0 mmol/L or a 25% increase from baseline
- Phosphate: ≥ 2.1 mmol/L in children or ≥ 1.45 mmol/L in adults or a 25% increase from baseline
- Calcium: ≤ 1.75 mmol/L or a 25% decrease from baseline

The clinical criteria focus on significant health impacts:
- Serum creatinine: ≥ 1.5 times the upper limit of normal
- Cardiac arrhythmias or sudden death
- Seizures

To establish a diagnosis for TLS, the calculator checks for combinations of these criteria. Specifically, the criteria are met if any two laboratory disturbances (from the choices above) are found to align with any clinical sign. An example would be elevated uric acid and potassium levels combined with a raised serum creatinine level or the occurrence of cardiac arrhythmias or seizures.

This structured approach ensures that all relevant parameters are considered, aiding healthcare providers in diagnosing TLS in patients potentially at risk. By using this calculator, clinicians can make informed decisions, potentially improving patient outcomes through timely intervention in cases of suspected tumor lysis syndrome.

The Cairo-Bishop criteria is a clinical calculator used to diagnose tumor lysis syndrome (TLS). This scoring system is applicable to patients with malignancies, particularly those with high-grade lymphomas and acute leukemias, who are at risk of developing TLS. The Cairo-Bishop criteria is clinically useful in identifying patients who have developed TLS, either spontaneously or following cancer treatment, by assessing changes in specific laboratory values including uric acid, potassium, phosphorus, and calcium levels. This calculator aids in risk stratification, guiding treatment decisions, and predicting prognosis. It does not have specific exclusion criteria, but it may be less applicable or accurate in patients with pre-existing electrolyte abnormalities or renal dysfunction not related to TLS.

Cairo-Bishop criteria for clinical tumor lysis syndrome

The Cairo-Bishop criteria are used to evaluate the presence of laboratory tumor lysis syndrome (TLS) by analyzing four key biochemical parameters. Each parameter has specific thresholds or percentage changes from baseline that determine whether it contributes to the overall score.

Here's how each parameter is considered:

- Uric Acid: A level of 476 µmol/L or more, or an increase of 25% or more from baseline, will meet the criteria.

- Serum Potassium: A level of 6 mmol/L or more, or a 25% or more increase from baseline, will meet the criteria.

- Serum Phosphorus: In children, a level of 2.1 mmol/L or more, and in adults, a level of 1.45 mmol/L or more, or a 25% or more increase from baseline, will meet the criteria.

- Serum Calcium: A level of 1.75 mmol/L or less, or a 25% or more decrease from baseline, will meet the criteria.

For each parameter that meets the criterion, a score of 1 point is added. The total score, which ranges from 0 to 4, reflects the number of criteria met.

Interpretation of the total score is simple:

- A score of 2 or more indicates that the criteria for laboratory TLS are met, signifying a significant risk or presence of the condition.

- A score of less than 2 suggests that the criteria for laboratory TLS are not met, indicating a lower risk.

The Cairo-Bishop criteria is a clinical calculator used to diagnose laboratory tumor lysis syndrome (TLS) in patients with malignancies. This scoring system is particularly applicable to patients with high-grade lymphomas and acute leukemias, which are at high risk for TLS, but it can be used in any patient with a malignancy who is at risk for this syndrome.

The Cairo-Bishop criteria for laboratory TLS is based on changes in laboratory values from baseline, including hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. The clinical utility of this calculator is to identify patients who are experiencing TLS, a potentially life-threatening complication of cancer treatment characterized by rapid release of intracellular components into the bloodstream. Early identification of TLS allows for prompt initiation of treatment to prevent serious complications such as renal failure, cardiac arrhythmias, seizures, and death.

There are no specific exclusion criteria for the use of the Cairo-Bishop criteria. However, it should be noted that this scoring system is not applicable to patients without malignancies or those who are not at risk for TLS. Additionally, the calculator may not be as accurate in patients with pre-existing electrolyte abnormalities or renal dysfunction, as these conditions can also cause changes in the laboratory values used in

Tumor lysis syndrome

Guidelines

Key sources